Profile data is unavailable for this security.
About the company
Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical research company. It is focused on the development of cancer treatments based on deoxyribonucleic acid (DNA)-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking and Enki platforms. Its drug development pipeline includes kt-2000AI and kt-3000 series. It is engaged in employing the proprietary Deep Docking AI Platform to rapidly screen billions of potential drug candidates against PARP (kt-2000AI) and other novel DDR targets to generate drug candidates that can be advanced to human trials or developed in collaboration with pharmaceutical partners. Its kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly (ADP)-ribose polymerase (PARP) and histone deacetylase in a single molecule. This novel approach has the potential to overcome treatment resistance and provide clinical benefit to cancer patients.
- Revenue in CAD (TTM)0.00
- Net income in CAD-8.36m
- Incorporated2019
- Employees--
- LocationRakovina Therapeutics Inc105 - 1008 Beach AvenueVancouver V6E 1T7CanadaCAN
- Phone+1 (604) 619-0225
- Fax+1 (604) 980-6264
- Websitehttps://www.rakovinatherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Appili Therapeutics Inc | 212.30k | -2.53m | 3.21m | 7.00 | -- | -- | -- | 15.12 | -0.0209 | -0.0209 | 0.0018 | -0.1287 | 0.1839 | -- | 0.786 | -- | -219.60 | -143.75 | -- | -1,382.22 | -- | -- | -1,194.04 | -2,076.82 | -- | -2.80 | -- | -- | -87.86 | -12.79 | 30.58 | -- | 16.92 | -- |
| Rakovina Therapeutics Inc | 0.00 | -8.36m | 3.38m | -- | -- | 1.79 | -- | -- | -0.5705 | -0.5705 | 0.00 | 0.0893 | 0.00 | -- | -- | -- | -158.14 | -- | -221.29 | -- | -- | -- | -- | -- | -- | -21.46 | 0.579 | -- | -- | -- | -55.86 | -- | -- | -- |
| Telo Genomics Corp | 0.00 | -2.71m | 4.02m | 8.00 | -- | -- | -- | -- | -0.0289 | -0.0289 | 0.00 | -0.0003 | 0.00 | -- | -- | -- | -517.19 | -98.53 | -51,970.82 | -111.33 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.2116 | -- | -- | -- |
| XORTX Therapeutics Inc | 0.00 | -2.63m | 4.04m | 3.00 | -- | 1.13 | -- | -- | -0.6406 | -0.6406 | 0.00 | 0.5131 | 0.00 | -- | -- | -- | -58.35 | -39.11 | -94.63 | -43.59 | -- | -- | -- | -- | -- | -- | 0.0291 | -- | -- | -- | -53.53 | -- | 48.96 | -- |
| StageZero Life Sciences Ltd | -100.00bn | -100.00bn | 4.81m | 40.00 | -- | -- | -- | -- | -- | -- | -- | -0.122 | -- | -- | -- | -- | -- | -135.76 | -- | -- | -- | -2.74 | -- | -246.92 | 0.0177 | -- | -- | -- | -25.12 | 55.93 | -52.53 | -- | -- | -- |
